DDInter603 DDInter1376
A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Droperidol {u} (Compound) resembles {v} (Compound) Haloperidol
Droperidol {u} (Compound) resembles {v} (Compound) Fluspirilene
Droperidol {u} (Compound) binds {v} (Gene) ADRA1A
Droperidol {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Droperidol {u} (Compound) downregulates {v} (Gene) CHIC2
Droperidol {u} (Compound) causes {v} (Side Effect) Altered state of consciousness
Droperidol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Droperidol {u} may lead to a major life threatening interaction when taken with {v} Naloxone
Droperidol (Compound) resembles Haloperidol (Compound)
Droperidol (Compound) resembles Fluspirilene (Compound)
Droperidol (Compound) binds ADRA1A (Gene)
Droperidol (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Droperidol (Compound) downregulates CHIC2 (Gene)
Droperidol (Compound) causes Altered state of consciousness (Side Effect)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Droperidol may lead to a major life threatening interaction when taken with Naloxone